[Cefazedone-results of a multicentre clinical test (author's transl)].
Cefazedone (Refosporin) was tested for efficacy and tolerance in 1161 patients. The trial was interrupted or unsuitable for evaluation in 54 cases. Diagnostical characteristics of the remaining 1107 patients tested for tolerance were: therapeutical and prophylactic use in surgery (37,5%) infections of the bronchial tract (30.8%), infections of the urogenital tract (17.9%), infections of the abdominocystic tract (6.2%), other infections (7,6%). Of the 1085 patients tested for efficacy--in 22 cases the trial was interrupted because of undesired side effects (exanthema, nausea, local intolerance)--87% concerned exclusively antibiotic therapy with cefazedone. Cefazedone was administered only twice daily i. v. Combined medication with other antibiotics--mainly amino glycosides--was highly efficient.
D001439:Bacteroides / Q000187:drug effects; D001660:Biliary Tract Diseases / Q000188:drug therapy*; D002437:Cefazolin / Q000031:analogs & derivatives*; D002511:Cephalosporins / Q000627:therapeutic use*; D004341:Drug Evaluation; D004755:Enterobacteriaceae / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D006801:Humans; D011514:Proteus vulgaris / Q000187:drug effects; D013211:Staphylococcus aureus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D014552:Urinary Tract Infections / Q000188:drug therapy*
D002511:Cephalosporins; C021341:cefazedone; D002437:Cefazolin
Cefazedon--Ergebnisse einer multizentrischen klinischen Studie.